InteRNA Technologies
OverviewSuggest Edit
InteRNA Technologies is a biotechnology company specializing in the development of RNA therapeutics for the treatment of cancer. It uses its microRNA (miRNA) discovery and functional validation platform to develop a drug candidate for treatment of patients with hepatocellular carcinoma, melanoma, triple-negative breast cancer, and lung cancer.
| Type | Private | |
| Founded | 2006 | |
| HQ | Nijmegen, NL | Map |
| Website | interna-technologies.com |
Recent NewsAll News
- InteRNA Technologies Announces U.S. FDA Clearance of IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3
- InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board
- InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board
- GBR Connect Series – Interview with Roel Schaapveld, InteRNA Technologies – US Pharma & Biopharma
Latest Updates
| Employees (est.) (Apr 2022) | 26 | |
| Cybersecurity rating | A | More |
Key People/Management at InteRNA Technologies
Michel Janicot
Acting Chief Development Officer
Roel Schaapveld
Chief Executive Officer
Laurens van Pinxteren
Chief Operating Officer
InteRNA Technologies Office Locations
InteRNA Technologies has an office in Nijmegen
Nijmegen, NL (HQ)
Jonkerbosplein 52
InteRNA Technologies Financials and Metrics
Summary Metrics
Founding Date | 2006 |
InteRNA Technologies total Funding | $22.3 m |
InteRNA Technologies latest funding size | $9.98 m |
Time since last funding | a year ago |
InteRNA Technologies investors | INKEF Capital, OostNL, Waterman Ventures, AurorA Science, Aglaia Oncology Funds |
InteRNA Technologies's latest funding round in February 2021 was reported to be $10 m. In total, InteRNA Technologies has raised $22.3 m
InteRNA Technologies Cybersecurity Score
InteRNA Technologies Online and Social Media Presence
InteRNA Technologies's Trends
InteRNA Technologies Blogs
December 02, 2021
InteRNA Technologies Announces U.S. FDA Clearance of IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3
-- IND approval enables clinical trial advancement and enrollment of dose expansion cohorts in the US -- Utrecht, The Netherlands, December 2, 2021 – InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today it recei…
October 19, 2021
InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board
-- Adding deep preclinical and clinical immuno-oncology expertise to expand InteRNA’s preclinical pipeline and accelerate clinical-stage lead candidate INT-1B3 -- Utrecht, The Netherlands, October 19, 2021 – InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based the…
October 12, 2021
InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board
Utrecht, The Netherlands, October 12, 2021 – InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today the appointment of Andrea van Elsas, PhD, as a new member of the Company’s Supervisory Board. Dr. van Elsas trans…
September 16, 2021
GBR Connect Series – Interview with Roel Schaapveld, InteRNA Technologies – US Pharma & Biopharma
Click here to read the interview with our CEO Roel Schaapveld in Global Business Report.
The post GBR Connect Series – Interview with Roel Schaapveld, InteRNA Technologies – US Pharma & Biopharma appeared first on InteRNA Technologies.
July 05, 2021
Vacancy Research Scientist
InteRNA Technologies – a clinical-stage biotechnology company based in Utrecht (The Netherlands) – is currently seeking a talented and highly motivated Research Scientist to join the company’s Research and Development group.InteRNA focuses on the discovery and development of RNA therapeutics (microR…
March 21, 2021
InteRNA and the renewed interest in RNA therapeutics in the March 2021 edition of MedNous
Nice read on the renewed interest in RNA (e.g. mRNA, gRNA, siRNA, saRNA, miRNA, antisense) -based therapeutics! Getting more and more an established drug class. Click here to read more
Het bericht InteRNA and the renewed interest in RNA therapeutics in the March 2021 edition of MedNous verscheen eer…
InteRNA Technologies Frequently Asked Questions
When was InteRNA Technologies founded?
InteRNA Technologies was founded in 2006.
Who are InteRNA Technologies key executives?
InteRNA Technologies's key executives are Michel Janicot, Roel Schaapveld and Laurens van Pinxteren.
How many employees does InteRNA Technologies have?
InteRNA Technologies has 26 employees.
Who are InteRNA Technologies competitors?
Competitors of InteRNA Technologies include Jiangsu Hansoh Pharmaceutical Group, Takeda Oncology and Shanghai Junshi Biosciences.
Where is InteRNA Technologies headquarters?
InteRNA Technologies headquarters is located at Jonkerbosplein 52, Nijmegen.
Where are InteRNA Technologies offices?
InteRNA Technologies has an office in Nijmegen.
How many offices does InteRNA Technologies have?
InteRNA Technologies has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies